New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination ...

When Anthony Cannella was first diagnosed with mantle cell lymphoma, his youngest child was in kindergarten. He was told that ...

Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

Berry softball coach Darrell Thomas leads team into North Regional next week while undergoing chemotherapy treatments.

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...